Valeo Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VPHIF research report →
Companywww.valeopharma.com
Valeo Pharma Inc. , a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.
- CEO
- Kyle Steiger
- IPO
- 2020
- Employees
- 70
- HQ
- Kirkland, QC, CA
Price Chart
Valuation
- Market Cap
- $9.87K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -5.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 24.26%
- Op Margin
- -31.96%
- Net Margin
- -51.58%
- ROE
- 95.58%
- ROIC
- -67.29%
Growth & Income
- Revenue
- $53.91M · 94.31%
- Net Income
- $-27,808,000 · -8.01%
- EPS
- $-0.32 · 0.00%
- Op Income
- $-17,228,000
- FCF YoY
- 39.97%
Performance & Tape
- 52W High
- $0.12
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 0.78
- Avg Volume
- 38.89K
Get TickerSpark's AI analysis on VPHIF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VPHIF Coverage
We haven't published any research on VPHIF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VPHIF Report →